Getting your player ready...
Mark Zaleski, Associated Press file
Mylan, currently in the cross-hairs over severe price hikes for its EpiPen, said Thursday that it will expand programs that lower out-of-pocket costs by as much as half.Re: Aug. 23 news story.
One wonders if eminent domain laws should be applied to terminate the patents of greedy companies in order to benefit society. We use this law to take private property for far less important public needs all the time. Of course, we’d pay the chemical companies a fair market price based on worldwide prices and actual production costs, but not their obvious greed.
I guess health care in America is defined: “If you can’t afford to get sick, then you better stay healthy. If you do get sick, oh bummer.”
Mark Parsons,Berthoud
Submit a letter to the editor via or check out our for how to submit by e-mail or mail.
